Clinical efficacy and safety of ambrocol oral liquid combined with pidotimod oral liquid in allergic asthma in children with mite
10.3969/j.issn.1005-1678.2017.04.072
- VernacularTitle:氨溴特罗口服液联合匹多莫德口服液治疗小儿螨虫过敏性哮喘的临床疗效及安全性
- Author:
Zhifang LIANG
;
Hongwei NING
- Keywords:
ambrocol oral liquid;
pidotimod oral liquid;
children;
mite allergic asthma;
clinical efficacy;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(4):220-222
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical curative effect and safety of ambrocol oral liquid combined with pidotimod oral liquid in the treatment of children with mite allergic asthma.Methods 54 cases of children with mite allergic asthma from December 2014 to December 2015 were selected and randomly divided into the control group and experimental group,27 cases in each group.On the basis of routine treatment,the control group was given pidotimod oral solution 10mL,once a day,oral; on the basis of the control group,the experimental group was treated with ambrocol oral solution 10mL,twice a day,oral.Interleukin-2(IL-2),interleukin-4(IL-4),immunoglobulin E(IgE)levels,the efficacy and safety of the two groups were measured before and after treatment.Results After treatment,compared with the control group,the serum levels of IL-2 were higher,and the levels of IL-4、IgE were lower in the experimental group,the difference was statistically significant(P<0.05),the treatment efficiency of the experimental group(92.59％)was significantly higher than that of the control group(81.48％),the difference was statistically significant(P<0.05).Conclusion The ambrocol oral liquid combined with pidotimod oral liquid can significantly improve the serum level of IL-2,and reduce the serum level of IL-4,IgE in children with mite allergic asthma,improve clinical efficacy.
